Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
AVL-301, CO-1686
print preview
bookmark
share with colleague
General Information
Company
Celgene Corp.
Description
Small molecule that inhibits the T790M EGFR mutant and the initial activating EGFR mutations
Molecular Target
Epidermal growth factor receptor (EGFR)
Mechanism of Action
Latest Stage of Development
Phase I/II
Indication
Non-small cell lung cancer (NSCLC)
Partner
Clovis Oncology Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy